About the Study
Welcome to the Solutions for Celiac website.
This NIH-funded clinical research study has been designed to assess the drink-based study medication latiglutenase and, in conjunction with a gluten-free diet, its ability to relieve common symptoms suffered by celiac disease patients typically experienced after accidental gluten exposure.
Latiglutenase is a combination of two enzymes that, when taken with meals, target and degrade gluten proteins in the stomach, rendering them inactive and less likely to cause the symptoms and intestinal damage associated with celiac disease.
As a study participant, you will be required to attend up to six (6) in-person clinic visits over the course of 26 weeks.
You will be required to take either the study medication or placebo three times per day (with breakfast, lunch and dinner) for 17 of the 26 weeks. The placebo resembles the study medication but does not contain the active ingredients. You will also be asked to eat a small mid-day snack once per week that sometimes contains gluten. This is done to simulate accidental gluten exposure that happens in everyday life. Finally, you will be asked to complete a daily electronic diary, recording your symptoms during study participation.
Participants will receive all study supplies, including the study medication, as well as all study-related tests and procedures, at no cost. Qualified participants may be reimbursed for study participation, including transportation and parking costs.
Help advance a therapy for celiac patients by clicking the “See If You Qualify” button to learn more. Should you pre-qualify for the study, a study staff member will contact you and share additional study details as well as answer any of your questions.
For further information, refer to our study page on ClinicalTrials.gov.